Key result
ACE gene ID genotype is ~82% more common in breast cancer patients than healthy controls.
Why the study?
The distribution of ACE gene I/D polymorphism in breast cancer patients and its association with clinicopathologic features and prognosis were investigated.
Is the ACE gene I/D polymorphism associated with breast cancer susceptibility and poor prognostic factors?
Case-Control (n=109)
Is the ACE gene I/D polymorphism associated with breast cancer susceptibility and poor prognostic factors?
Absolute Event Rate: 42.1% vs 23.1%
p-value: p=0.03
The ACE gene ID genotype is more frequent in breast cancer patients, and the DD genotype may be associated with poor prognostic factors such as negative hormone receptor status.
ACE I/D variants merit exploration as breast cancer biomarkers; hypothesis-generating and should not yet change practice.
The aims of the present study were to investigate the distribution of the insertion/deletion (I/D) polymorphism of the angiotensin-converting enzyme (ACE) gene in breast cancer patients and the association between ACE genotypes and clinicopathologic features, as well as their effects on prognosis. We assessed the I/D polymophism of the ACE gene by using polymerase chain reaction from peripheral blood in breast cancer and healthy age-matched women. The clinicopathologic parameters of breast cancer patients were obtained from medical records. Of the 57 patients, 31 (54.4%) had DD, 24 (42.1%) had ID, and 2 (3.5%) had II genotypes. In control subjects, 33 (63.5%) had DD, 12 (23.1%) had ID, and 7 (13.4%) had II genotypes. The ID genotype was seen more commonly in breast cancer patients (p = .03). When the combination of ID and II genotypes was used as a reference group, the DD genotype was associated with negative hormone receptor status (p = .003), tumor size (p = .054), and lymph node involvement (p = .07) but not histologic high grade and c-erb B2 overexpression. These results suggest that the DD genotype may accompany poor prognostic factors and influence the tumor course.
No takes yet. Share an insight, caveat, or question.
Yaren et al. (2007) conducted a case-control in Breast cancer (n=109). ACE gene ID genotype vs. Healthy controls was evaluated on Presence of ACE gene ID genotype (p=0.03). The ACE gene ID genotype was more common in breast cancer patients than healthy controls (42.1% vs 23.1%, p=0.03), while the DD genotype was associated with negative hormone receptor status (p=0.003).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: